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Sterol 27-hydroxylase (CYP27A1) is involved in bile acid synthesis and
cholesterol homoeostasis. Cyp27a1(/)/Apolipoprotein E (/) double
knockout mice (DKO) fed a western diet failed to develop atherosclerosis.
Caveolin-1 (CAV-1), the main component of caveolae, is associated with
lipid homoeostasis and has regulatory roles in vascular diseases. We
hypothesized that liver CAV-1 would contribute to the athero-protective
mechanism in DKO mice. Cyp27a1(+/+)/ApoE(/) (ApoE KO),
Cyp27a1(+/)/ApoE(/) (het), and DKO mice were fed a western diet for
2 months. Atherosclerotic plaque and CAV-1 protein were quantified in
aortas. Hepatic Cav-1 mRNA was assessed using qPCR, CAV-1 protein by
immunohistochemistry and western blotting. Total hepatic and plasma
cholesterol was measured using chemiluminescence. Cholesterol efflux was
performed in RAW264.7 cells, using mice plasma as acceptor. CAV-1 pro-
tein expression in aortas was increased in endothelial cells of DKO mice
and negatively correlated with plaque surface (P < 0.05). In the liver, both
CAV-1 protein and mRNA expression doubled in DKO, compared to
ApoE KO and het mice (P < 0.001 for both) and was negatively correlated
with total hepatic cholesterol (P < 0.05). Plasma from DKO, ApoE KO
and het mice had the same efflux capacity. In the absence of CYP27A1,
CAV-1 overexpression might have an additional athero-protective role by
partly overcoming the defect in CYP27A1-mediated cholesterol efflux.
Sterol 27-hydroxylase (CYP27A1), a mitochondrial
enzyme of the cytochrome P450 family, catalyses
the hydroxylation of cholesterol at C27 to form
27-hydroxycholesterol (27-OHC) and cholestenoic acid.
CYP27A1 plays a major role in cholesterol homoeosta-
sis by metabolizing cholesterol into bile acids (BA).
27-OHC is an endogenous inhibitor of the rate-limiting
enzyme of cholesterol biosynthesis [HMGCoA reduc-
tase (HMGR)]. CYP27A1 is also involved in cholesterol
efflux [1], the first and rate-limiting step in reverse
cholesterol transport (RCT). The process of RCT chan-
nels cholesterol from extrahepatic tissues, including
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vessel walls, to the liver and subsequently eliminates it
by conversion into BA. Through removal of excess
cholesterol from the arterial wall, RCT may prevent the
development of atherosclerosis [2]. In previous in vitro
studies, our group has demonstrated that CYP27A1 is
directly involved in cholesterol efflux [3,4].
To study the athero-protective role of CYP27A1
in vivo, Cyp27a1 KO mice were crossed with ApoE
KO mice known for their propensity to spontaneously
develop atherosclerosis, and the resulting offspring
were fed a western diet (WD) for 3 and 6 months [5].
The atherosclerosis observed in ApoE KO was abol-
ished in Cyp27a1/ApoE double knockout (DKO) mice.
DKO mice had hepatomegaly, elevated plasma HDL-
Cholesterol (HDL-C), reduced cholesterol absorption
and enhanced cholesterol elimination via increased
Cyp7a1 and Cyp3a11 mRNA expression. The ATP-
binding cassette transporter ABCA1 (ABC-A1) and
scavenger receptor B1 (SR-B1) implicated in choles-
terol efflux were unaffected.
Caveolin-1 (CAV-1) is the major constituent of cave-
olae, which are 50–100 nm flask-shaped invaginations
of the plasma membrane present in most mammalian
cells. It has been suggested that CAV-1 is intimately
involved in cholesterol trafficking [6]. In vitro, studies
have confirmed the role of CAV-1 in RCT, since over-
expression of Cav-1 in HepG2 cells increases the for-
mation of caveolae and enhances cholesterol efflux [7].
Furthermore, CAV-1 has an additional athero-protec-
tive role, as overexpression of Cav-1 in vivo in the liver
of C57BL/6J mice injected with adenoviruses encoding
Cav-1 leads to increased plasma HDL-C [8].
The aim of the study was to analyse CAV-1 localiza-
tion and expression in DKO mice and to investigate the
effect of CYP27A1 downregulation on CAV-1 expres-
sion in liver, aorta and macrophages and the ability of
plasma to act as acceptor in a cholesterol efflux system.
Due to the known association of CAV-1 with liver lipid
metabolism, we hypothesized that increased liver
CAV-1 expression would lead to increased triglyceride
accumulation, increased lipogenesis and low-density
lipoprotein (LDL) internalization.
Thus, increased hepatic CAV-1 could be considered
as an additional athero-protective mechanism, com-
pensating for the defect in cholesterol efflux in DKO
mice, in which Cyp27a1 is not expressed.
Experimental procedures
Materials
Haematoxylin Gill no. 3 (GHS316), eosin Y aqueous
(HT110216) and concanavalin A were from Sigma-Aldrich
(Buch, Switzerland). Cell culture medium was from Gibco
(Lucerne, Switzerland). Primers were from Microsynth
(Balgach, Switzerland), probes from Roche Diagnostics
(Rotkreuz, Switzerland) and TaqMan assays from Life
Technologies-Applied Biosystems (Lucerne, Switzerland).
Animals
Animal experimentation was approved by the Ethics Com-
mittee for Animal Experiments of the Veterinary Adminis-
tration of the Canton of Berne, Switzerland, and
conformed to the rules of the Swiss Federal Act on Animal
Protection for the Care and Use of Laboratory Animals.
Cyp27a1(+/+)/ApoE (/) (ApoE KO), Cyp27a1(+/)/
ApoE(/) (het) and Cyp27a1(/)/ApoE(/) (DKO) mice
were bred/genotyped as previously published [5]. Mice were
maintained under a standard 12 : 12-h light–dark cycle and
fed ad libitum. At the age of 6 weeks, males were fed a
WD for 2 months, containing 21% fat and 0.15% choles-
terol (D-12079B; Provimi Kliba AG, Kaiseraugst, Switzer-
land). Animals were fasted for 4 h before euthanasia by
pentobarbital injection (300 mgkg1, Esconarkon, Streuli
Pharma AG, Uznach, Switzerland). Animals were weighed,
blood was collected into a tube containing 20–50 U hep-
arin; livers and other organs were removed, washed with
PBS, weighed and fixed in formalin at 4 °C or frozen in liq-
uid nitrogen and stored at 70 °C. Heart and aorta were
dissected, fixed in 4% paraformaldehyde for 24 h, trans-
ferred to PBS and stored at 4 °C.
Isolation of peritoneal macrophages
In a second cohort of mice fed for 1 month with WD, peri-
toneal macrophages were collected 4 days following injec-
tion of concanavalin A (1.6 mgkg1 intraperitoneal). Cells
were harvested in PBS and grown in macrophage serum-
free medium supplemented with 100 lgmL1 penicillin–
streptomycin, 1% L-glutamine, 1% sodium pyruvate
100 mM, 10% FBS, and 10 ngmL1 recombinant human
macrophage colony-stimulating factor (PeproTech, Rocky
Hill, NJ, USA). Cells were incubated for 3 h at 5% CO2
and 100% humidity to allow specific macrophage adhesion.
Adherent cells were washed three times with PBS and used
for mRNA isolation.
Characterization of atherosclerotic lesions
Lesions from aortas were stained with haemotoxylin and
eosin (H&E) and quantified, as previously described [5].
Biochemical analyses
Plasma cholesterol (TC), triglycerides (TG), LDL-Choles-
terol (LDL-C) and high-density lipoprotein-Cholesterol
(HDL-C) were quantified using commercial kits (Wako
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Chemicals GmbH, Neuss, Germany). In liver homogenates,
TG were measured using a kit (BioVision, Mountain View,
CA, USA) as well as TC, cholesterol and cholesterol esters
(Calbiochem-Merck Millipore, Zug, Switzerland). All assays
were conducted blind to group and in duplicate; the inter-
and intracoefficient of variances were less than 10% and
5% respectively. Total BA were analysed in liver homoge-
nates and faeces by gaschromatography–mass spectrometry
(GC-MS) using our previously described method [5].
Cholesterol absorption by faecal dual-isotope
method
In a third cohort of mice fed WD, gavage was performed
with 100 lL soybean oil containing 0.1 lCi [4-14C] choles-
terol and 0.2 lCi [22,23-3H] b-sitosterol. After gavage, each
mouse was individually housed in a cage covered with
Whatman paper and had free access to food and water.
Faeces were collected daily for 3 days. Samples were
extracted by saponification with 5 M KOH in 50% ethanol
and heated at 80 °C for 1 h. Lipids were extracted by Folch
method. The extracted lipids were transferred into scintilla-
tion vials and isotopes were counted in b-counter. The per-
centage of cholesterol absorption was calculated as follows:
14C
3H dose ratio 14C3H faeces ratio
14C
3H dose ratio
 100:
RNA extraction and real-time PCR
RNA extraction and real-time PCR in liver homogenates
and isolated macrophages were conducted according to
standard procedures previously described [5]. Real-time
PCR was performed in triplicate with 100 ng cDNA/reac-
tion. Primers and probes are those reported in our previous
study [5] or from the Universal Probe library (Roche).
b-Actin (AM1720) was used as the internal standard. Quan-
tification was performed by the relative quantification
method using ApoE KO as calibrator.
Immunohistochemistry (IHC)
Immunohistochemical staining was performed as previously
described [5,9]. Slides were incubated with primary antibody
(Anti-CAV-1- Santa Cruz Biotechnology, INC, Heidelberg,
Germany) ([c-894)] diluted for liver: 1 : 200 and aorta:
1 : 1500 in 1% BSA in PBS overnight at 4 °C. Slides were
subsequently incubated with goat anti-rabbit antibody
(1 : 200; Santa Cruz Biotechnology, INC [sc-2004]), fol-
lowed by DAB chromogen (Dako, Hamburg, Germany)
and counterstaining with haematoxylin. A negative control
was performed by incubation without primary antibody.
All slides were blinded to group and assessed by the
same observer (YTM). For analysis of sections, digital
images of five randomly selected, high-power (9 400
magnification) fields were captured on NIS-Elements
F2.20 microscope (Nikon Ltd, Kingston Upon Thames,
Surrey, UK). Quantification of the specific staining was
performed using the POSITIVE PIXEL ALGORITHM OF APERIO
IMAGE SCOPE software [10]. Accurate discrimination of
immunolabelled regions was confirmed visually.
Western blotting (WB)
Protein extraction using ~ 100 mg of powdered liver was per-
formed in RIPA buffer containing protease and phosphatase
inhibitor cocktail (10 lLmL1; Sigma-Aldrich). For immun-
odetection, CAV-1 (1 : 600 in TBST with 5% nonfat dry
milk powder and 2% BSA) and horseradish peroxidase-con-
jugated anti-rabbit (1 : 10 000; Santa Cruz Biotechnology,
INC [sc-2004]) antibodies were used. Proteins were visualized
by chemiluminescence agent using ECL Detection Reagents
(GE Healthcare, Little Chalfont, UK). For internal stan-
dard, b-actin [1 : 10 000 Santa Cruz Biotechnology, INC
(sc-69879)] was used. Densitometry of exposed films was per-
formed using IMAGEJ software and the ratio of CAV-1/b-actin
protein was expressed in relative light units.
Cholesterol efflux
Cholesterol efflux was performed in vitro in RAW264.7
cells using 2% of various mice plasma for 2 h [3,4,7].
Cholesterol efflux was calculated as percentage of labelled
cholesterol released to the medium divided by the
amount of total cholesterol in the medium and cells in
each well. The assay was performed in quadruplicates
and assay variability was controlled with a sample of
pooled plasma.
Statistical analysis
All tests were performed using the STATISTICAL PACKAGE FOR
SOCIAL SCIENCES (SPSS) for Windows version 22.0 (IBM Swit-
zerland Ltd, Zu¨rich, Switzerland) and GRAPHPAD PRISM ver-
sion 6 (La Jolla, CA, USA). Summary data are presented
as mean  standard deviation (SD). One-way ANOVA
followed by either Tukey’s or Gabriel’s post hoc tests were
used after normality was confirmed using the Kolmogorov–
Smirnov and Shapiro–Wilk tests. Correlations between the
parameters were tested with a Pearson’s Rank correlation
tests. The null hypothesis was rejected when P < 0.05.
Results
Effect of Cyp27a1 gene dosage on atherosclerotic
phenotype at an early stage of atherosclerosis
ApoE KO, het and DKO mice were fed WD for
2 months; body and organ weights, plasma and
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hepatic lipids, hepatic BA and atherosclerotic plaque
were analysed (Table 1).
Het mice were heavier than their littermates
(P = 0.003; Table 1). Liver weights and liver/body
weight ratios were increased, whereas spleen weights
decreased in DKO mice when compared to ApoE KO
(P < 0.05 for all). The weights of kidneys, lungs and
brains did not differ among the genotypes (Table 1).
Plasma composition analysis revealed that DKO
had a twofold lower plasma TC concentration than
both ApoE KO and het mice (P < 0.0001). In DKO
mice, HDL-C and TG concentrations increased by
60% and 65%, respectively, whereas LDL-C concen-
tration tended to decrease (Table 1).
In the liver, TC concentration was decreased by ̴
60% in DKO mice (P = 0.0005). The decrease was due
to cholesterol and not cholesterol ester. Hepatic TG
concentration increased by 60% in DKO mice
(P = 0.002). Hepatic BA were significantly reduced in
DKO mice compared to both ApoE KO and het mice
(P = 0.0002; Table 1).
Cholesterol absorption was measured by faecal
dual-isotope incorporation. Following gavage with
[4-14C] cholesterol and [22,23-3H] b-sitosterol, DKO
mice excreted significantly more faecal [4-14C] choles-
terol than their ApoE KO littermates (P < 0.0001,
Table 1). Cholesterol absorption was threefold lower
in DKO mice (P < 0.0001, Table 1), which also
excreted significantly less BA than their ApoE KO lit-
termates (Table 1).
In the aorta, there was no atherosclerosis in DKO
mice (Table 1). The presence of cholesterol clefts and
fibrosis were observed only in het and ApoE KO mice
(data not shown).
CAV-1 expression in aorta and heart
Very little or no CAV-1 protein expression was
observed in vascular cells making up the plaques in
ApoE KO mice (Fig. 1A). In addition, in areas where
plaques were present, increased CAV-1 was localized
around vessels in both the atrium (Fig. 1B) and ventri-
cles (Fig. 1C). Conversely, in DKO aortas without pla-
ques, CAV-1 was observed in endothelial cells
(Fig. 1D), and only low expression was detected in the
atrium (Fig. 1E) and ventricles (Fig. 1F).
Table 1. Effect of CYP27A1 expression on body and organ weight, plasma and liver lipids composition, intestinal cholesterol absorption and
atherosclerosis in ApoE-KO, het and DKO mice.
Parameter
ApoE KO het DKO
Pn = 6 n = 7 n = 6
Weight
Body (g) 27.7  0.74 29.9  1.62* 27.3  1.12 0.003
Liver (g) 1.37  0.21 1.66  0.17 1.83  0.40* 0.03
Spleen (g) 0.16  0.03 0.16  0.01 0.11  0.02* 0.01
Lung (g) 0.17  0.01 0.16  0.02 0.16  0.02 NS
Kidney (g) 0.16  0.04 0.17  0.01 0.17  0.02 NS
Brain (g) 0.45  0.02 0.45  0.02 0.47  0.01 NS
Plasma
TC (mmolL1) 18.5  4.94 18.4  2.59 8.8  1.26*** < 0.0001
LDL-C (mmolL1) 12.9  5.76 13.2  5.35 7.8  1.91 0.1
HDL-C (mmolL1) 0.50  0.13 0.51  0.12 0.81  0.07*** 0.0002
TG (mmolL1) 1.17  0.34 0.96  0.27 1.93  0.66* 0.004
Liver
TC (lgmg1) 10.7  1.44 9.5  1.52 6.7  1.34*** 0.0005
Cholesterol (lgmg1) 9.1  0.87 7.5  1.04* 5.3  0.68*** < 0.0001
Cholesterol ester (lgmg1) 1.60  0.78 1.97  0.84 1.31  0.77 0.36
TG (nmolmg1) 42.2  3.64 32.8  11.0 67.9  19.68* 0.002
BA (ngg1 liver) 13 996  8646 7922  4965 3026  1250** 0.002
Faeces
Cholesterol (DPM) 111 312  20 788 120 409  26 383 218 516  51 930*** < 0.0001
Cholesterol absorption (%) 55  4 57  10 18  6.93*** < 0.0001
BA (lg/24 h) 238.2  51.3 250.5  96.6 102  18.9 0.0019
Aorta
Lesion surface (mm2) 0.061  0.034 0.045  0.026 0.003  0.005296** 0.0024
Results are presented as means  SD. *P < 0.05, **P < 0.01, ***P < 0.001 versus ApoE-KO.
Statistically significant values are represented in bold.
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CAV-1 expression in liver
Cav-1 mRNA expression was significantly increased in
DKO mice liver (mean  SD: 4.42  0.78) compared
to both ApoE KO (1.07  0.44; P < 0.01) and het
(1.13  0.25; P < 0.05) mice (Fig. 2A).
The amount of CAV-1 protein quantified by WB
with a molecular weight of 22 kDa was about three-
fold higher in DKO (1.79  0.33) and twofold higher
in het (0.99  0.24) than in ApoE KO (0.58  0.19;
P < 0.05 for all; Figs 2B and 3A) mice. The increased
amount of CAV-1 was also confirmed by IHC
(0.98  0.01 in DKO versus 0.93  0.02 in ApoE KO
and 0.91  0.05 in het, P < 0.05; Figs 2C and 3B).
CAV-1 was localized around the sinusoid and the
micro/macrovesicles (Fig. 3B).
Effect of Cyp27a1 gene dosage on expression of
genes involved in cholesterol and lipid homoeostasis,
cholesterol efflux, inflammation and oxidative stress in
the liver and cholesterol efflux in isolated macro-
phages.
All gene expression results are summarized in
Table 2. In the liver, the most upregulated genes were
Cyp7a1 and Cyp3a11, two genes involved in BA
synthesis and cholesterol metabolism. Genes involved
in cholesterol homoeostasis ([HMGR; Hmgcr], sterol
regulatory element-binding protein 2 [Srebf2], LDL
receptor [Ldlr] and the transcription factor peroxisome
proliferator-activated receptor gamma [PPAR c;
Pparc]) were also increased in DKO mice (P < 0.05
for all). The lipogenesis and triglyceride accumulation
markers (Acetyl CoA carboxylase [ACC; Acc], fatty
acid synthase [FAS; Fasn] and diacylglycerol acyltrans-
ferase 1 [DGAT; Dgat1]) were also increased in DKO
mice (P < 0.01 for both). Small heterodimer partner
(SHP; Nr0b2) was reduced in DKO mice (P < 0.05
versus het). Farnesoid X receptor (FXR; Nr1 h4) and
sterol regulatory element-binding transcription factor 1
(SREBP1c; Srebf1) did not change between groups
(ANOVA P > 0.05 for all).
For hepatic genes involved in cholesterol efflux,
Cyp27a1 was confirmed to be absent in DKO mice
and reduced by 50% in het mice. After 2 months of
WD, Abca1 (gene for ATP-binding cassette [ABC]
A1), Abcg1 (gene for ABCG1) and Scarb1 (gene for
SR-B1) were reduced; Nr1 h3 (gene for Liver X recep-
tor a) remained unchanged in DKO mice.
Aorta Atrium Ventricle
A B C
D E F
G H I
20 μm
ApoE KO 
DKO
NegaƟve control
Fig. 1. CAV-1 protein expression in mice
aorta and heart with and without
atherosclerotic plaques. Aorta (A, D, G),
atrium (B, E, H) and ventricles (C, F, I)
sections were stained for CAV-1 by IHC.
(A) Almost no positive staining was
observed in vascular cells making up
plaques. In ApoE KO mice, CAV-1
expression, which is localized around
vessels in both the (B) atrium and (C)
ventricles (black arrows), is increased. In
DKO mice, higher CAV-1 expression was
seen in (D) endothelial cells (black arrows),
with low expression in both (E) atrium and
(F) ventricles. (G–I) are negative controls;
4009 magnification.
5FEBS Open Bio (2016) ª 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
L. Zurkinden et al. Increased Caveolin-1 in Cyp27a1/ApoE-deficient mice
Among the genes involved in inflammation in the
liver, only tumour necrosis factor a (Tnfa) expression
was lower in DKO mice compared to ApoE KO
mice (P = 0.02). All other inflammatory genes (Il1b
for IL-1b, Il6 for IL-6, Il10 for IL-10, Nfkb for
nuclear factor kappa B) and oxidative stress genes
(Nrf2 for nuclear factor erythroid 2-related factor 2
[NRF2] and Nos3 for endothelial nitric oxide syn-
thase [eNOS]) were not different between groups
(ANOVA P > 0.05 for all).
In isolated macrophages, the expression of all
genes involved in cholesterol efflux was unchanged,
except, as expected, Cyp27a1 (ANOVA P = 0.0015,
Table 2).
Cholesterol efflux
The ability of plasma obtained from mice of all three
genotypes to efflux cholesterol was tested in RAW
264.7 cells. The percentage of cholesterol efflux was
slightly, but not significantly, higher when plasma
from DKO were used (5.9  1.5 versus 5.0  0.9 in
ApoE KO and 5.2  0.5 in het; mean  SD in %).
Correlation analyses
Cav-1 mRNA expression positively correlated with
both CAV-1 protein expression data (WB: R2 = 0.317;
r = 0.563; P = 0.02; IHC: R2 = 0.283; r = 0.532;
P = 0.03), as did the WB and IHC results (R2 = 0.232;
r = 0.482; P = 0.04).
Both liver Cav-1 mRNA and CAV-1 protein, mea-
sured by WB, negatively correlated with atheroscle-
rotic plaques in all mice overall (mRNA: R2 = 0.477;
r = 0.691; protein: R2 = 0.423; r = 0.655; P < 0.005
for both). Total liver cholesterol concentrations also
negatively correlated with liver Cav-1 mRNA and both
protein expression measurements (mRNA: R2 = 0.47;
r = 0.74; protein (WB): R2 = 0.26; r = 0.51; protein
(IHC): R2 = 0.27; r = 0.52; P < 0.05 for all).
Finally in DKO mice, there was positive associations
between Cav-1 with Scarb1, Ldlr and Pparc (Scarb1:
Fig. 2. Genotype-induced effect on expression of CAV-1 in the liver. (A) Cav-1 mRNA expression was quantified by real-time PCR, using b
Actin as internal standard. CAV-1 protein was quantified by WB (B) and IHC (C). Data are shown as mean  SD. For statistical difference,
*P < 0.05, **P < 0.01, ***P < 0.001.
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r = 0.80; R2 = 0.65; P = 0.048; Ldlr: r = 0.82;
R2 = 0.55; P = 0.046; Pparc: r = 0.82; R2 = 0.68;
P < 0.0001).
Discussion
This study confirms our previous results observed in
older DKO animals, highlighting the early age of
atherosclerosis in ApoE KO and het mouse models[5].
This is also the first report on the effect of CYP27A1
suppression on CAV-1 expression in vivo in DKO
mice. These results suggest that increased CAV-1
expression in the liver and in aortic endothelial cells is
an additional protective mechanism against atheroscle-
rosis development in DKO mice fed a WD.
The increased gene and protein expression of hepatic
CAV-1 in DKO mice initially suggested a contribution
to eliminate cholesterol excess from the liver, as seen
by decreased total liver/free cholesterol and the nega-
tive association between total liver cholesterol and
Cav-1 mRNA/protein expression. In addition, as
shown by our reported changes in intestinal cholesterol
absorption, the absence of CYP27A1 expression in the
intestine seems to be largely contributing to the
antiatherosclerotic phenotype observed in our DKO
mice.
Increased CAV-1 might also compensate for the
defect of CYP27A1-mediated cholesterol efflux.
Among the different cholesterol efflux mechanisms, the
CAV-1-dependent pathway involves the transfer of
cholesterol from intracellular compartments to caveo-
lae for efflux [11]. Cholesterol transport to the cell sur-
face in cells expressing CAV-1 is much faster than in
the same cells lacking CAV-1 [11]; in cells overexpress-
ing CAV-1, cholesterol efflux is increased [7]. In our
study, the ability of plasma to act as an acceptor in a
cholesterol efflux system was not changed when DKO
plasma was used. This indicates that the decreased
CYP27A1 expression was compensated by other path-
ways of cholesterol efflux. Since Abca1, Abcg1 and
Scarb1 were rather decreased, we conclude that the
CAV-1-mediated pathway was enhanced, in line with
the increased staining of CAV-1 in endothelial cells of
aortas from DKO mice. Second, as plasma acceptor
capacity in DKO mice is not changed, the reduced
atherosclerotic plaque formation in DKO mice is
mainly due to lower plasma cholesterol, attributed to
reduced intestinal absorption. Interestingly, the
A
B
ApoE KO het DKO
CAV-1 
22 kDa
β-ACTIN
43 kDa
ApoE KO
Het NEG 
DKO
20 µm 20 µm
20 µm20 µm
Fig. 3. Genotype-induced effect on
expression of CAV-1 in the liver.
Representative WB (A) and IHC (B) of
CAV-1 in liver. CAV-1 was detected as a
22-KDa protein. The IHC staining localized
to sinusoids (black arrows) and around
micro/macrovesicular steatosis (black
arrowheads); 4009 magnification; scale
bar = 20 lm.
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absence of Cyp27a1 in macrophages was not compen-
sated by the overexpression of other genes involved in
cholesterol efflux. This suggests that, taken together,
intestinal and hepatic changes account for the
antiatherosclerotic lipid status in these DKO mice.
Caveolin 1 has previously been reported to be asso-
ciated with the LDLR and the process of influx of
LDL-C from the circulation to the liver [12]. Our data
in DKO mice showing a strong positive correlation
between hepatic Cav-1 and Lldr mRNA expression
supports this. We can thus speculate that a cholesterol
efflux-independent mechanism takes place to reduce
circulating LDL-C and sequester it into the liver for
subsequent degradation, as suggested by others [13].
Hepatic CAV-1 expression has significant effects on
OxLDL metabolism and on lipoprotein receptor levels
[14]. This observation could explain why no differences
were observed for Scarb1 between the groups and also
why Ldlr expression was increased in DKO mice, illus-
trating the protective mechanism of CAV-1 (summa-
rized in Fig. 4). Therefore, increased hepatic CAV-1 in
the DKO mice could also be beneficial for the efficient
removal of circulating oxLDL, preventing atheroscle-
rosis development.
Table 2. Genotype effects on expression of genes involved in lipid metabolism, inflammation and oxidative stress in liver and on cholesterol
efflux in liver and macrophages.
Parameter
ApoE KO het DKO
Pn = 6 n = 7 n = 6
Cholesterol and lipid homoeostasis
Liver
Cyp7a1 1.15  0.73 2.88  1.03 9.15  3.10*** < 0.0001
Cyp3a11 1.00  0.08 0.93  0.25 18.32  0.60*** < 0.0001
Hmgcr 1.02  0.24 1.27  0.40 9.20  2.36*** < 0.0001
Srebf2 1.09  0.40 1.71  0.76 4.65  1.99** 0.003
Ldlr 1.02  0.20 1.75  0.86 2.90  1.05** 0.003
Pparc 1.03  0.24 0.70  0.08 3.30  1.01*** < 0.0001
Nr1 h4 1.00  0.29 0.90  0.31 1.08  0.36 NS
Nr0b2 1.10  0.73 1.40  0.30 0.22  0.09 0.0203
Srebf1 1.14  0.64 2.21  1.33 1.50  0.88 NS
Acc 1.01  0.18 0.79  0.08 1.40  0.20** < 0.0001
Fasn 1.10  0.50 0.98  0.48 3.90  0.88*** < 0.0001
Dgat1 1.01  0.18 0.85  0.15 1.29  0.25 0.0087
Cholesterol efflux
Liver
Cyp27a1 0.80  0.20 0.50  0.26* 0.00  0.00*** < 0.0001
Nr1 h3 1.01  0.19 1.05  0.12 1.05  0.11 NS
Abca1 1.01  0.23 1.02  0.06 0.64  0.05** 0.01
Abcg1 1.04  0.19 0.85  0.22 0.52  0.12*** 0.0005
Scarb1 0.91  0.14 0.88  0.21 0.67  0.11 NS
Macrophages
Cyp27a1 1.00  0.39 0.95  0.53 0.00  0.00 0.0015
Cav-1 1.13  0.73 0.59  0.39 0.54  0.10 NS
Nr1 h3 1.04  0.29 1.49  0.52 1.49  0.20 NS
Abca1 1.05  0.36 1.16  0.43 0.89  0.28 NS
Abcg1 1.03  0.25 1.30  0.62 1.89  0.28 NS
Scarb1 1.02  0.21 1.10  0.20 1.13  0.24 NS
Inflammation and oxidative stress
Liver
Tnfa 1.10  0.42 1.00  0.28 0.55  0.22* 0.02
Il1b 1.04  0.28 1.31  0.41 1.10  0.66 NS
Il6 1.12  0.63 1.25  0.94 1.93  0.83 NS
Il10 1.09  0.42 1.13  0.40 1.20  0.27 NS
Nfkb 1.01  0.19 0.84  0.09 0.89  0.23 NS
Nrf2 1.05  0.30 0.75  0.05 0.92  0.19 NS
Nos3 1.01  0.20 0.84  0.07 0.81  0.17 NS
Results are presented as means  SD. *P < 0.05, **P < 0.01, ***P < 0.001 versus ApoE-KO.
Statistically significant values are represented in bold.
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Bile acid increases FXR activity and the repressive
effects of SHP thus preventing TG build-up [15]. The
reduced BA concentrations and lower hepatic Nr0b2
(gene for SHP) expression observed in DKO mice
could also contribute to the hepatic and circulating
TG accumulation. Furthermore, BA are associated
with plasma lipid composition and with lower trans-
hepatic BA flux resulting in lower LDL-C, higher
HDL-C and TG concentrations [16], as is the case in
our DKO mice (Fig. 4).
In our DKO mice, the increased hepatic CAV-1
appears to provide additional beneficial effects in pro-
moting TG accumulation in the liver and increasing
the expression of genes involved in lipogenesis (Fig. 4).
CAV-1
Cholesterol
7-OHC 27-OHC 
Bile acids
SREBP1C
Fay acids
Triglycerides 
DGAT
ACC
FAS
SHP
SREBP2
HMGR
Acetyl CoA
LDL
TNFα
CYP7A1CYP27A1
FXR
PPARγ
Plasma lipid composion 
HDL LDL TG
Athero-protecve 
eﬀect 
Fig. 4. Beneficial effects of hepatic CAV-1 on atherosclerosis protection in DKO mice. Atherosclerosis is mainly driven by high circulating
cholesterol concentration, low HDL-C and high LDL-C. In plasma of DKO mice fed WD, the low levels of LDL-C can be attributed to
increased SREBP2 in the liver, which increases LDLR expression and LDL-C uptake. CAV-1 is also associated with the LDLR and the
process of influx of LDL from the circulation to the liver. In DKO mice, SHP is downregulated, suppressing the inhibitory effect on SREBP1c
and CYP7A1 as well as increasing TG and BA biosynthesis. The increased hepatic CAV-1 expression appears to provide additional beneficial
effects in promoting hepatic TG accumulation via increased DGAT expression and increasing hepatic gene expression of lipogenic markers
(ACC and FAS). Pparc was also increased in DKO mice and correlated positively with Cav-1 mRNA expression, supporting its role in
upregulating CAV-1. The lower TNFa, in combination with higher CAV-1 expression in the liver further supports the potential anti-
inflammatory role for CAV-1. In the absence of 27-OHC in DKO mice, the rate-limiting enzyme of cholesterol biosynthesis, HMGR is
suppressed and cholesterol production is increased. Cholesterol is still metabolized to BA via the classical pathway of BA synthesis initiated
by CYP7A1. The reduced transhepatic BA flux in DKO mice results in lower circulating LDL-C, higher HDL-C and TG concentrations; this
leads to reduced atherosclerotic plaque formation. Green and red boxes represent up- and downregulation respectively.
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This might be an adaptive response to deal with both
CYP27A1 suppression and a WD, thus restricting the
accumulation of cytotoxic free fatty acid as has been
suggested [17]. Similarly, the beneficial function of
CAV-1 was further highlighted by a previous study on
hypercholesterolaemic rabbits treated with antennape-
dia-CAV-1 peptide reporting markedly less fat accu-
mulation in the liver [18].
Several studies have tended to investigate the rather
complex role of CAV-1 leading to evidence of pro- or
antiatherogenic function depending on localization,
degree of expression and stage of atherosclerosis devel-
opment. In ApoE KO mice fed a WD and infected for
4 weeks with AdPPARc, CAV-1 expression was
induced in aortic vascular endothelial cells, smooth
muscle cells and macrophages, and atherosclerotic
lesions were attenuated [19]. These results are in line
with our DKO mice in which Pparc was increased and
correlated positively with Cav-1 mRNA expression [19].
In contrast, Cav-1/ApoE double KO mice, with a
> 2-fold increase in LDL-C [20], were protected from
atherosclerosis, despite hypercholesterolaemia, underly-
ing the role of CAV-1 in transcytosis of LDL-C across
endothelial cells. Pavlides et al. also reported a cell-
specific role for CAV-1 [21]; its absence in macrophage
was proatherogenic, whereas its absence in endothelial
cells was athero-protective. In our DKO mice, the
main effect of Cyp27a1 suppression is a change in
plasma lipid composition consisting of increased
HDL-C and decreased LDL-C, as well as hepatic his-
tology and lipid composition. We conclude that
changes in hepatic CAV-1 expression have a stronger
impact on the atherosclerotic phenotype and that those
in endothelial cells compensate the defect in cholesterol
efflux.
In addition, CAV-1 also appears to be an important
mediator in response to inflammatory stimuli within
the endothelium [22]. Elevated CAV-1 protein expres-
sion in aortas of diet-induced obese rats fed a WD
correlated with a decreased eNOS activity [23]. In our
DKO mice with increased CAV-1, Nos3 expression
tended to be reduced (Table 2). The decreased Tnfa
gene expression further suggests CAV-1 has an
anti-inflammatory role in the liver (Table 2, Fig. 4).
To conclude, the advancement in the understanding
of CAV-1 and its influence on lipid homoeostasis and
atherosclerosis could be a new approach for the treat-
ment of metabolic syndrome. Our proposed mecha-
nism (Fig. 4) on the beneficial effects of increased
hepatic CAV-1 on protection against atherosclerosis in
DKO mice remains to be verified in humans with
reduced CYP27A1 activity. The role of CAV-1 in the
intestine still needs to be investigated, particularly in
DKO mice following restoration of hepatic BA synthe-
sis, by examining the correlation between alterations in
lipid profiles, liver and intestinal expression of CAV-1,
and atherosclerotic plaque formation.
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